TY - GEN AU - González-Costello,J. AU - Ripoll-Vera,T. AU - Eiros,R. AU - Llàcer,P. AU - Lozano-Bahamonde,A. AU - Peña-Peña,M.L. AU - Santas,E. AU - Yun,S. KW - Acoramidis KW - Amyloidosis KW - Tafamidis KW - Transthyretin cardiac amyloidosis KW - Vutrisiran T1 - Transthyretin-related cardiac amyloidosis. A review of current treatments and future prospects TI - Amiloidosis cardiaca por transtirretina: una revisión de los tratamientos actuales y de las perspectivas futuras LA - spa PY - 2026/// T2 - REC: CardioClinics SN - 2605-1575 PB - Elsevier Espana S.L.U AB - Transthyretin amyloidosis (ATTR) is a progressive and potentially fatal systemic disease caused by the extracellular accumulation of amyloid fibrils derived from transthyretin (TTR). Transthyretin cardiac amyloidosis (ATTR-CA), one of its main manifestations, leads to signs and symptoms of heart failure. Although traditionally an underdiagnosed disease, the availability of non-invasive diagnostic techniques has led to a substantial increase in the number of patients diagnosed with ATTR-CA. In turn, the availability of effective treatments with survival benefits has improved the prognosis for these patients. In this review, we address relevant aspects of the aetiopathogenesis of ATTR-CA, patient screening and diagnosis, as well as the therapeutic options currently available (disease-modifying treatments: tafamidis, acoramidis and vutrisiran) and under development. DO - 10.1016/J.RCCL.2026.04.001 UR - https://portalcientifico.uah.es/documentos/6a1b790fe3ade41446334ac2 DP - Dialnet - Portal de la Investigación ER -